Skip to main content

Medical Devices & Technology

Globus Medical Names Keith Pfeil CEO as Leadership Transition Aligns with Strong Q2 Sales Performance

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced a significant leadership transition, positioning its executive team for continued strategic growth in the musculoskeletal technology sector. Effective July 18, 2025, Keith Pfeil assumed the role of President and Chief Executive Officer, succeeding Daniel Scavilla, who stepped down to pursue another opportunity. Additionally, Kyle Kline was appointed Senior Vice President and Chief Financial Officer.

Leadership Shifts Focused on Strategic Growth

Globus Medical to Release Q2 2025 Financial Results and Host Investor Call on August 7

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has scheduled the announcement of its financial results for the second quarter ended June 30, 2025, for Thursday, August 7, 2025, after market close. The musculoskeletal technology leader will publish the earnings release on its investor relations website at www.investors.globusmedical.com.

Investor Call Scheduled for August 7

Globus Medical Expands Surgical Power Portfolio with DuraPro™ and Advanced Navigation Solutions

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced the expansion of its Excelsius™ navigation capabilities with the introduction of DuraPro™, a next-generation oscillating system designed to enhance surgical precision while safeguarding delicate tissue. As part of the company’s Power Portfolio, DuraPro™ aims to optimize procedural workflows by combining advanced oscillating technology with integrated navigation.

Advancing the High-Speed Drill Market with Next-Generation Oscillation

Globus Medical Authorizes $500 Million Share Repurchase to Strengthen Shareholder Value

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. (NYSE: GMED), a global leader in musculoskeletal solutions, today announced a significant strategic initiative with the authorization of a share repurchase program of up to $500 million of the company’s outstanding common stock. The move underscores Globus Medical’s confidence in its long-term business fundamentals and commitment to delivering sustained value for shareholders.

Strategic Response to Market Valuation Trends

KaVo Launches DIAGNOcam Vision Full HD for Simultaneous Triple Dental Diagnostics

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – July 21, 2025 – KaVo Dental has launched the DIAGNOcam Vision Full HD, an innovative dental diagnostic device that enables simultaneous capture, presentation, and storage of three diagnostic images in less than one second. Designed to integrate seamlessly into existing clinical workflows, this advanced system supports dental professionals in enhancing diagnostic accuracy while improving patient communication and care.

Revolutionizing Dental Diagnostics with Real-Time Triple Imaging

KaVo Expands Surgical Portfolio with Launch of SURGmatic S15 L Pro

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – July 21, 2025 – KaVo has introduced the SURGmatic™ S15 L Pro high-speed contra-angle surgical handpiece, positioning itself at the forefront of surgical innovation with a product designed to meet a broad spectrum of clinical demands. Engineered for both surgical and non-surgical applications, the SURGmatic S15 L Pro underscores KaVo’s commitment to performance, reliability, and operator efficiency in demanding clinical environments.

Enhanced Performance for Complex Surgical Applications

Roche and Broad Clinical Labs Join Forces to Advance Next-Gen Sequencing in Neonatal Care

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced a new strategic collaboration with Broad Clinical Labs, aiming to accelerate the adoption of its next-generation Sequencing by Expansion (SBX) technology, with an initial focus on trio-based whole genome sequencing for critically ill newborns and their biological parents. The partnership signifies a pivotal move in expanding genomics-enabled healthcare and precision medicine at scale.

Philips Expands European Access to Minimally Invasive Heart Procedures with Launch of VeriSight Pro 3D ICE Catheter

Submitted by J. Mikhail on

SHERIDAN, WYOMING – May 19, 2025 – Royal Philips has announced the European launch of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter, marking a significant step in transforming structural heart procedures through minimally invasive, real-time imaging technology. Already established in the U.S. market, this cutting-edge device supports more efficient, patient-friendly interventions without requiring general anesthesia — a major development for healthcare providers facing rising demands in structural heart disease care.

Philips Secures €1 Billion in Oversubscribed Bond Offering to Strengthen Debt Position and Support Green Initiatives

Submitted by J. Mikhail on

SHERIDAN, WYOMING – May 19, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the successful pricing of a €1 billion dual-tranche bond issuance under its European Medium Term Note (EMTN) program, marking a strategic step to reinforce its capital structure and advance sustainable investment goals.